COLYTE w. FLAVOR PACKS Rx
Generic Name and Formulations:
Polyethylene glycol 3350 60g, sodium chloride 1.46g, potassium chloride 0.745g, sodium bicarbonate 1.68g, sodium sulfate 5.68g, flavor 0.851g/pack (orange, lemon lime, cherry); per liter of soln; pwd for reconstitution (add 1 flavor pack before reconstitution).
Indications for COLYTE w. FLAVOR PACKS:
Bowel cleansing before colonoscopy or barium enema exam.
After fasting for >3hrs, 240mL orally every 10mins or 20–30mL/min by NG tube until fecal discharge is clear. Usual dose 3–4L. Only clear liquids until exam.
GI obstruction or perforation. Gastric retention. Toxic colitis. Toxic megacolon. Ileus.
Severe ulcerative colitis. Impaired gag reflex. Semi- or unconsciousness. Risk of aspiration or regurgitation. Correct fluid and electrolyte abnormalities prior to initiation. Increased risk of arrhythmias (eg, history of prolonged QT, uncontrolled arrhythmias, recent MI, unstable angina, CHF or cardiomyopathy); do pre-dose and post-colonoscopy ECGs. History of seizures. Rule out GI obstruction or perforation. Maintain adequate hydration. Renal impairment. Pregnancy (Cat.C). Nursing mothers.
Isosmotic bowel cleanser.
Concomitant drugs that may increase the risk of fluid and electrolyte disturbances or adverse events. Drugs administered within 1hr of start of Colyte may not be absorbed. Increased risk of ischemic colitis with concomitant stimulant laxatives.
Nausea, abdominal fullness or bloating, cramps, vomiting, anal irritation; serious: colonic mucosal ulceration, ischemic colitis; rare: arrhythmias.
Colyte w. Flavor Packs—4L (disposable jug w. 3 flavor packs)
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry
- Medical Schools Phase Out Lectures as Education Shifts Outside the Classroom
- Clonidine Testing Is Safe and Reliable for Diagnosing Growth Hormone Deficiency